-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $96

Benzinga·11/11/2026 14:29:05
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $120 to $96.